SAN DIEGO, June 28 /PRNewswire/ -- ChemDiv, Inc. and Nerviano Medical Sciences (NervianoMS), Milano, Italy, announced an extension of their collaboration to an additional 2 year program. NervianoMS will use services of ChemDiv for building and enriching its portfolio of proprietary discovery chemical libraries. Such compound libraries are instrumental in enhancing the access to novel bioactive compounds.
This agreement capitalizes on ChemDiv's success in contributing its world largest small molecule collection and library designs set to NervianoMS discovery chemistry assets, as well as strengths and experience in managing global medicinal and synthetic chemistry collaborations. NervianoMS has also entrusted ChemDiv with supporting NervianoMS inventory with global logistic services. Financial terms were not disclosed.
"Our business relationship with ChemDiv is entering a phase of joint scientific endeavours with ambitious goals of innovation. The strengths of High-Throughput Screening and Combinatorial Chemistry at NervianoMS shall be complemented with ChemDiv's fully aligned synthetic productivity. NervianoMS is a world leader in oncology-focused R&D and one of a handful that performs HTS with a throughput of millions of data points per year. It is also one of only a couple in the world that conducts HTS campaigns running assays in parallel. Useful new chemical entities will be generated and tested with an efficiency level of the highest standard," said Francesco Colotta, VP of Oncology , NervianoMS.
"Collaboration with NervianoMS, a leader in area of oncology-focused drug discovery and development, further expands our capabilities to elaborate and accomplish custom synthesis projects to fulfill all requirements of our partners. Our alliance with Nerviano has already produced very promising results and we expect it to strengthen our competitive position," said Alexander Kiselyov, Executive VP of Research & Development, ChemDiv.
About Nerviano Medical Sciences
Nerviano Medical Sciences (NervianoMS) is a world leader in oncology-focused R&D. Nearly 700 highly skilled and experienced scientists, technicians and managers work on oncology R&D projects from target validation through to clinical phase IIa. Currently NMS pipeline includes two anticancer drugs in advanced phase II, two additional targeted candidates in phase I and several projects in preclinical stage. Moreover, NervianoMS delivers drug development and pharmaceutical services to partners and clients in the pharmaceutical and biotechnology industry. For additional information, please visit http://www.nervianoms.com
About ChemDiv, Inc.
ChemDiv, Inc. (ChemDiv) is a global chemistry-driven contract research organization focused on the delivery of new scientific innovation, products and services that meet the drug discovery needs of its partners. ChemDiv provides partners with access to Discovery outSource(tm), a full service drug discovery capabilities encompassing: medicinal chemistry, pre-clinical development, synthetic chemistry, diverse and focused screening libraries, as well as global logistics. For additional information, please visit http://www.chemdiv.com.
ChemDiv, Inc.; Nerviano Medical SciencesCONTACT: Irina Tyrnova, Business Development Executive of ChemDiv, Inc.,+1-858-794-4860, or fax, +1-858-794-4931, it@chemdiv.com; or MariaD'Acquino, Public Affairs and Communications of Nerviano Medical Sciences,+39 0331 581013, or fax, +39 0331 581370, maria.dacquino@nervianoms.com
